REG-Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
Key Highlights
- ➤$252.0 million cash and investments extend Oculis’ runway into 2H 2029
- ➤PREDICT-1 randomized 176 patients; Licaminlimab topline results expected around year-end 2026
- ➤PIONEER-1 advances globally toward registrational optic neuritis trial enrollment
- ➤Privosegtor IND clearance for acute MS relapses expected in Q4 2026
- ➤Q3 R&D expenses rose to $18.5 million; nine-month net loss narrowed to $71.7 million
Expert Statements
Riad Sherif, M.D., Chief Executive Officer of Oculis
“The third quarter marked notable progress across our late-stage pipeline, advancing us towards several major value-driving milestones with significant opportunities to provide first-in-kind therapies and transform patient care in multiple neuro-ophthalmology and ophthalmology diseases.”
Riad Sherif, M.D., Chief Executive Officer of Oculis
“PREDICT-1 topline results are expected around year-end; if positive, they would position Licaminlimab to potentially become the first precision medicine in ophthalmology, specifically targeting TNFR1-mediated dry eye disease.”
Riad Sherif, M.D., Chief Executive Officer of Oculis
“I’m particularly encouraged by the continued momentum in Privosegtor PIONEER-1 registrational trial in optic neuritis, an indication backed by FDA Breakthrough Therapy designation and EMA Priority Medicines designation.”
Riad Sherif, M.D., Chief Executive Officer of Oculis
“Furthermore, the new translational biomarker data presented in the late-breaking abstract session at the ACTRIMS-ECTRIMS joint conference reinforced our rationale for expanding into broader neuro-axonal indications.”
* Licaminlimab (PREDICT-1): Patient randomization is now complete in the registrational symptoms trial evaluating Licaminlimab for TNFR1-mediated dry eye disease (DED). Topline results are anticipated around year-end 2026. * Privosegtor (PIONEER-1): Advancing global registrational trial in optic neuritis (ON), reinforced by new biomarker data supporting its neuroprotective potential. IND clearance to initiate trials in acute multiple sclerosis (MS) relapses is expected in Q4 2026. * R&D Day scheduled for December 8, featuring a comprehensive update on the Company’s late-stage pipeline and insights from world-renowned experts in ophthalmology, neuro-ophthalmology, and neurology. * Cash, cash equivalents, and short-term investments of $252.0 million as of September 30, 2026, providing cash runway into 2H 2029. ZUG, Switzerland, November 3, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced results for the third quarter ended September 30, 2026, and provided an overview of the Company’s progress.
Get started
Create a free account to read the full story.